The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a naturally occurring tryptamine found in various plants and in the parotoid gland secretion of the Sonoran Desert toad (Incilius alvarius). The Introduction summarises ethnobotanical reports and biochemical traces that have prompted interest in 5-MeO-DMT, while noting that strong evidence for longstanding indigenous use is limited. The compound has been detected alongside other indole alkaloids such as DMT in plant materials, and its presence in toad venom has driven recreational and experimental use in Western contexts. The authors also review suggestions, and conflicting data, about possible endogenous production of 5-MeO-DMT in mammals and humans, concluding that further evidence is needed to support any physiological role. This paper sets out to survey the clinical pharmacology, subjective effects, neurophysiological actions, and potential therapeutic applications of 5-MeO-DMT, drawing on receptor binding and preclinical studies, observational and survey data, and the limited clinical research to date. The review aims to identify mechanistic pathways (serotonergic, neuroendocrine, immunological, and neuroplasticity-related) that could plausibly underlie reported mental health effects and to highlight gaps that need addressing before clinical development can proceed safely and effectively.

The extracted text does not present a dedicated Methods section or a clear description of a formal search strategy, inclusion/exclusion criteria, or systematic review procedures. From the prose it is evident that the paper is a narrative review synthesising multiple types of evidence: in vitro receptor binding studies, animal experiments, observational and web-based surveys, prospective naturalistic studies in healthy volunteers, and early-phase clinical trials and registrations. The authors integrate findings from molecular pharmacology (receptor affinity and metabolism), preclinical behavioural and neuroendocrine experiments in rodents, cross-sectional and prospective human surveys (including a web-based survey of N=515), small prospective observational cohorts (examples reported with n=42 and n=11), and registered but early-stage clinical trials. Because explicit methods for literature identification and quality appraisal are not reported in the extracted text, readers should understand this as a narrative synthesis rather than a systematic review or meta-analysis.

Pharmacology and metabolism: Two receptor binding studies using human cloned receptors reported that 5-MeO-DMT is a non-selective serotonin receptor agonist with highest affinity for the 5-HT1A receptor (reported Kd/affinity ~1.9–3 nM). The compound shows roughly 300–1000 fold greater selectivity for 5-HT1A over 5-HT2A, which contrasts with many classic psychedelics whose experiential effects are primarily attributed to 5-HT2A activation. Additional, lower-affinity interactions with the serotonin transporter and dopamine or noradrenergic transporters were noted. Metabolically, 5-MeO-DMT is primarily inactivated by monoamine oxidase A (MAO-A) via oxidative deamination and is O-demethylated by CYP2D6 to produce bufotenine, an active metabolite with higher affinity for 5-HT2A and substantial 5-HT1A affinity. Concurrent MAOI use can block deamination, increasing exposure and prolonging effects, with potential for exaggerated serotonergic outcomes. Subjective effects, routes and temporal profile: Human reports and observational research indicate that 5-MeO-DMT produces perceptual distortions (visual, auditory, time), amplified emotions, intense mystical/"peak" experiences and feelings of ego-dissolution. Smoked or vapourised administrations produce an extremely rapid onset (peaks within seconds) and a short duration of effects typically lasting about 15–20 minutes. Intramuscular (IM) injection has been reported to onset over 1–6 minutes and last up to 60 minutes, yielding a slower and often milder subjective course; intranasal administration reportedly onsets in 5–7 minutes and can last 45–60 minutes. The magnitude of the experience varies substantially between individuals; approximately 20–30% of ceremonial participants report low-to-medium psychedelic intensity, which may reflect dose, inhalation technique, or preparation variability. Acute adverse reactions reported across studies include fear, anxiety, nausea, vomiting, headache, trembling, confusion and transient loss of body perception. Short-lived reactivations or "flashbacks" (sensory disturbances or brief re-experiencings) have been described during the week following exposure, generally experienced as neutral or positive in large samples; rare cases of psychosis have been reported, sometimes in conjunction with other tryptamines. Observational and early clinical outcomes: A web-based survey of N=515 reported infrequent lifetime use (typically less than once a year) and predominantly spiritual motivations; 90% of respondents endorsed moderate-to-strong mystical-type experiences and few reported craving or substantial legal, medical or psychiatric problems. Two prospective naturalistic studies described rapid improvements in self-reported depression, anxiety, stress and mindfulness-related capacities after a single inhalation of toad venom or synthetic 5-MeO-DMT. In one study (n=42) reductions in depression, anxiety and stress and increases in mindfulness and life satisfaction were reported at 24 hours and, for some measures, up to 4 weeks post intake; higher acute ego-dissolution correlated with larger improvements. A smaller follow-up (N=11) found immediate decreases in depression and sustained increases in mindfulness at 7 days, with anxiety and stress significantly reduced at that time point. Cross-sectional surveys of respondents with diagnosed psychiatric disorders reported high proportions reporting improvement after 5-MeO-DMT: PTSD 79%, depression 77%, anxiety 69%, substance use problems 63% and obsessive–compulsive disorder 53%, with only 2–10% reporting worsening. In a separate sample of people with depression (n=149) and anxiety (n=173), around 80% reported improvement after group use of 5-MeO-DMT; few reported worsening. Neurophysiological effects: Early rodent work showed marked effects on pituitary prolactin (PRL) release: robust acute increases in PRL followed by a longer-term inhibitory phase, interpreted as centrally mediated and involving serotonergic mechanisms and subsequent dopaminergic modulation. Comparative work indicated stronger PRL effects for 5-MeO-DMT than for bufotenine or DMT, partly reflecting in vivo stability and blood–brain barrier transport differences. The review situates 5-MeO-DMT within a broader literature linking serotonergic psychedelics to promotion of neuroplasticity, noting Brain-derived neurotrophic factor (BDNF) as a key mediator: single-dose effects on serum BDNF have been observed with other psychedelics (LSD, ayahuasca), implying a plausible pathway for antidepressant-like actions. Immune and inflammatory regulation are proposed to occur via two main downstream mechanisms: neuroendocrine modulation (for example via PRL) and direct effects on immune cells and intracellular pathways mediated by 5-HT2A and sigma-1 receptor (Sig1R) signalling. Toad venom versus synthetic 5-MeO-DMT: Bufo alvarius secretion contains a complex mixture of pharmacologically active compounds (bufagins, catecholamines, bufotenine and other sterols). The authors note that clinical improvements reported in users of toad venom and synthetic 5-MeO-DMT have been similar, suggesting 5-MeO-DMT is the principal active therapeutic ingredient, but they emphasise that the variable and complex composition of venom complicates development and raises ethical and ecological concerns about toad extraction. Emerging clinical development and safety signals: Reckweg and colleagues and other groups have registered early clinical studies of inhalable and intranasal formulations; two clinical studies on inhalable formulations were reported as completed and safety data have been published. Early clinical observations suggest cognitive and psychomotor function return to baseline quickly after the short-lived psychoactive period and adverse events are generally mild and transient, although details of trial designs and outcomes are limited in the extracted text.

Reckweg and colleagues interpret the assembled literature as providing a signal that 5-MeO-DMT may have therapeutic utility in mental health, principally because it can reliably induce intense "peak" or mystical experiences that observational and prospective studies have associated with rapid improvements in measures of depression, anxiety, stress and wellbeing. They highlight a mechanistic plurality: psychological effects (the intensity of acute subjective experience as a predictor of outcome), neuroplastic and neurotrophic effects (BDNF-related pathways), neuroendocrine modulation (notably biphasic prolactin effects), and immunoregulatory actions mediated via 5-HT2A and Sig1R as plausible contributors to therapeutic outcomes. The authors position 5-MeO-DMT as potentially advantageous compared with longer-acting psychedelics because of its rapid onset and short duration, which could lower treatment time and cost and allow for practical dose-escalation strategies when a first exposure fails to elicit a peak experience. They also note translational research avenues, including comparisons with non-hallucinogenic analogues derived from 5-MeO-DMT chemistry (for example tabernanthalog) that produced pro-plasticity and anti-addictive effects in rodents, raising the possibility of separating psychoplastogenic benefits from subjective effects. Key limitations and uncertainties acknowledged include the predominance of observational, survey-based and small naturalistic cohorts rather than large, controlled clinical trials; heterogeneity in dosing, route, and context in field reports; variable composition of toad venom; incomplete understanding of the relative contributions of 5-HT1A versus 5-HT2A signalling to subjective and therapeutic effects; and insufficient evidence for endogenous production or physiological roles of 5-MeO-DMT in humans. The authors call for both commercially funded clinical development to bring standardised formulations into trials and independent academic research to probe basic neurophysiological mechanisms, emphasising that fundamental studies are less likely to be covered within industry programmes. They also reiterate ethical and ecological concerns about relying on toad venom as a source and prefer synthetic formulations for drug development. Overall, the discussion frames 5-MeO-DMT as an intriguing short-acting psychedelic with preliminary human and preclinical signals warranting further controlled investigation, while cautioning that robust mechanistic and clinical evidence is still required before clinical adoption.